Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial

被引：9
|
作者：
Chi, Y. [1 ]
Gao, M. [2 ]
Zhang, Y. [3 ]
Shi, F. [4 ]
Cheng, Y. [5 ]
Guo, Z. [6 ]
Ge, M. [7 ]
Qin, J. [8 ]
Zhang, J. [9 ]
Li, Z. [10 ]
Zhou, X. [11 ]
Huang, R. [12 ]
Chen, X. [13 ]
Liu, H. [14 ]
Cheng, R. [15 ]
Xu, Z. [16 ]
Zheng, X. [2 ]
Li, D. [2 ]
Tang, P. [17 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Clin Res Ctr Canc, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Dept Thyroid & Neck Oncol, Tianjins Clin Res Ctr Canc, Natl Clin Res Ctr Canc,Key Lab Canc Prevent & The, Tianjin, Peoples R China
[3] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Head & Neck Surg Dept,Jiangsu Canc Hosp, Nanjing, Peoples R China
[4] Hunan Canc Hosp, Nucl Med Ctr, Thyroid Tumour Internal Med Dept, Changsha, Peoples R China
[5] Jilin Canc Hosp, Dept Med Oncol, Changchun, Jilin, Peoples R China
[6] Sun Yat Sen Univ, Ctr Canc, Head & Neck Surg, Guangzhou, Peoples R China
[7] Chinese Acad Sci, Head & Neck Surg Inst Canc & Basic Med ICBM, Canc Hosp,Univ Chinese Acad Sci,Zhejiang Canc Hos, Zhejiang Prov Peoples Hosp,Peoples Hosp,Hangzhou, Hangzhou, Peoples R China
[8] Zhengzhou Univ, Affiliated Canc Hosp, Thyroid & Head & Neck Surg, Henan Canc Hosp, Zhengzhou, Peoples R China
[9] Harbin Med Univ, Canc Hosp, Thyroid Surg Ward, Harbin, Peoples R China
[10] China Med Univ, Liaoning Tumor Hosp & Inst, Tumor Hosp, Dept Head & Neck Surg, Shenyang, Peoples R China
[11] Chongqing Univ, Canc Hosp, Chongqing Canc Hosp, Head & Neck Surg, Chongqing, Peoples R China
[12] Sichuan Univ, West China Hosp, Nucl Med, Chengdu, Peoples R China
[13] Capital Med Univ, Beijing Tongren Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China
[14] Fujian Canc Hosp, Head & Neck Dept, Fuzhou, Peoples R China
[15] Kunming Med Univ, Affiliated Hosp 1, Dept Thyroid Surg, Kunming, Yunnan, Peoples R China
[16] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Head & Neck Surg,Natl Canc Ctr, Beijing, Peoples R China
[17] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Canc Hosp, Dept VIP,Natl Canc Ctr, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA88
引用
收藏
页码：S1215 / S1215
页数：1
相关论文
共 50 条
  • [1] Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
    Chi, Yihebali
    Zheng, Xiangqian
    Zhang, Yuan
    Shi, Feng
    Cheng, Ying
    Guo, Zhuming
    Ge, Minghua
    Qin, Jianwu
    Zhang, Jiewu
    Li, Zhendong
    Zhou, Xiaohong
    Huang, Rui
    Chen, Xiaohong
    Liu, Hui
    Cheng, Ruochuan
    Xu, Zhengang
    Li, Dapeng
    Tang, Pingzhang
    Gao, Ming
    CLINICAL CANCER RESEARCH, 2023, 29 (20) : 4047 - 4056
  • [2] Anlotinib in locally advanced or metastatic radioiodinerefractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial
    Chi, Y.
    Gao, M.
    Zhang, Y.
    Shi, F.
    Cheng, Y.
    Guo, Z.
    Ge, M.
    Qin, J.
    Zhang, J.
    Li, Z.
    Zhou, X.
    Huang, R.
    Chen, X.
    Liu, H.
    Cheng, R.
    Xu, Z.
    Zheng, X.
    Li, D.
    Tang, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1347 - S1347
  • [3] Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial
    Li, Dapeng
    Chi, Yihebali
    Chen, Xiaohong
    Ge, Minghua
    Zhang, Yuan
    Guo, Zhuming
    Wang, Jun
    Chen, Jie
    Zhang, Jiewu
    Cheng, Ying
    Li, Zhendong
    Liu, Hui
    Qin, Jianwu
    Zhu, Jingqiang
    Cheng, Ruochuan
    Xu, Zhengang
    Zheng, Xiangqian
    Tang, Pingzhang
    Gao, Ming
    CLINICAL CANCER RESEARCH, 2021, 27 (13) : 3567 - 3575
  • [4] Anlotinib treatment in locally advanced or metastatic medullary thyroid carcinoma: A multicenter, randomized, double-blind, placebo-controlled phase IIB trial.
    Li, Dapeng
    Tang, Ping Zhang
    Chen, Xiaohong
    Ge, Minghua
    Zhang, Yuan
    Guo, Zhuming
    Wang, Jun
    Shi, Feng
    Zhang, Jiewu
    Cheng, Ying
    Li, Zhendong
    Liu, Hui
    Qin, Jianwu
    Huang, Rui
    Cheng, Ruochuan
    Xu, Zhengang
    Chi, Yihebali
    Zheng, Xiangqian
    Gao, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] VANDETANIB IN LOCALLY ADVANCED OR METASTATIC DIFFERENTIATED THYROID CANCER (PAPILLARY OR FOLLICULAR; DTC): A RANDOMIZED, DOUBLE-BLIND PHASE II TRIAL
    Leboulleux, S.
    Bastholt, L.
    Krause, T. M.
    De La Fouchardiere, C.
    Tennvall, J.
    Awada, A.
    Gomez, J. M.
    Carrasco, A. Tisseron
    Licour, M.
    Schlumberger, M. J.
    ANNALS OF ONCOLOGY, 2010, 21 : 315 - 315
  • [6] Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma (ESCC): A randomized, double-blind, multicenter phase II trial.
    Huang, Jing
    Xiao, Juxiang
    Fang, Wentao
    Lu, Ping
    Fan, Qingxia
    Shu, Yongqian
    Feng, Ji Feng
    Zhang, Shu
    Ba, Yi
    Liu, Ying
    Bai, Chunmei
    Bai, Yu-Xian
    Tang, Yong
    Song, Yan
    He, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [7] Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
    Leboulleux, Sophie
    Bastholt, Lars
    Krause, Thomas
    de la Fouchardiere, Christelle
    Tennvall, Jan
    Awada, Ahmad
    Manuel Gomez, Jose
    Bonichon, Francoise
    Leenhardt, Laurence
    Soufflet, Christine
    Licour, Muriel
    Schlumberger, Martin J.
    LANCET ONCOLOGY, 2012, 13 (09): : 897 - 905
  • [8] A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China
    Gao, M.
    Ge, M.
    Xu, Z.
    Ji, Q.
    Shi, F.
    Qin, J.
    Wang, F.
    Chen, G.
    Zhang, Y.
    Huang, R.
    Tan, J.
    Huang, T.
    Li, S.
    Lv, Z.
    Lin, Y.
    Guo, Z.
    Kubota, T.
    Suzuki, T.
    Ikezawa, H.
    Zheng, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S1407 - S1407
  • [9] Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
    Brose, Marcia S.
    Nutting, Christopher M.
    Jarzab, Barbara
    Elisei, Rossella
    Siena, Salvatore
    Bastholt, Lars
    de la Fouchardiere, Christelle
    Pacini, Furio
    Paschke, Ralf
    Shong, Young Kee
    Sherman, Steven I.
    Smit, Johannes W. A.
    Chung, John
    Kappeler, Christian
    Pena, Carol
    Molnar, Istvan
    Schlumberger, Martin J.
    LANCET, 2014, 384 (9940): : 319 - 328
  • [10] A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid Carcinoma
    Sehgal, Kartik
    Serritella, Anthony
    Liu, Mofei
    Oneill, Anne
    Nangia, Chaitali
    Pappa, Theodora
    Demeure, Michael J.
    Worden, Francis P.
    Haddad, Robert I.
    Lorch, Jochen
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024,
12345